The orphan nuclear receptor Nur77 regulates diverse cellular activities, including cell proliferation, differentiation and apoptosis. The c-Jun N-terminal kinase (JNK) have a dual role in controlling the function of Nur77. While JNK-mediated phosphorylation of Nur77 positively regulates its translocation to the mitochondria to induce apoptosis, it negatively regulates the stability of Nur77. The underlying mechanism for the dual role of JNK in regulating Nur77, however, is unclear. Here, we report that E3 ubiquitin ligase Smad ubiquitination regulatory factor 1 (Smurf1) prevents Nur77 degradation through mediating its unconventional ubiquitination, thereby mitigating the JNK-mediated downregulating effect, which leads to Nur77 accumulation and subsequent translocation to mitochondria to trigger apoptosis. In this process, protein kinase A (PKA)-mediated phosphorylation of Smurf1 at Thr306 is a prerequisite step. Accordingly, cyclic AMP/PKA signaling switches the fate of Nur77 from degradation to triggering apoptosis in chemotherapy drug cisplatin-treated cells. Hence, our study revealed a novel mechanism, by which PKA/Smurf1 antagonizes the downregulating effect of JNK on Nur77, leading to the accumulation of Nur77 for apoptosis induction triggered by cisplatin.
INTRODUCTION
The orphan nuclear receptor Nur77 (also named NR4A1, TR3 or NGFI-B) is a member of the subfamily of nuclear hormone receptor 4A, and is involved in diverse cellular activities, including cell proliferation, differentiation and apoptosis. 1 In addition to being critical for T-cell receptor-mediated apoptosis in immature T cells and T-cell hybridomas, 2, 3 Nur77 has also been found necessary for apoptosis induced by many anticancer drugs, such as all-trans retinoic acid, 6-(3-(1-adamantyl)-4-hydroxyphenyl)-2-naphtha-lenecarboxylic acid (AHPN, also called CD437) and cisplatin in various types of tumor cell lines, such as pancreatic, hepatocellular, melanoma, ovarian and gastric cancer cells. [4] [5] [6] [7] [8] [9] [10] Nur77 is heavily phosphorylated inside the cell, and multiple kinases have been implicated in its phosphorylation, including c-Jun N-terminal kinase (JNK), p90-kDa ribosomal S6 kinase, extracellular signal-regulated kinases, AKT, protein kinase A (PKA) and glycogen synthase kinase-3b. [11] [12] [13] [14] [15] [16] [17] [18] Phosphorylation of Nur77 at various sites by different kinases has been shown to modulate various activities of Nur77 ranging from DNA binding, transcriptional activation, to subcellular localization. 19 Certain anticancer drugs can induce translocation of Nur77 from nucleus to mitochondria, where it interacts with and converts Bcl-2 to a pro-apoptotic molecule to trigger cytochrome c release. 19, 20 JNKmediated Nur77 phosphorylation is essential for the Nur77 translocation. 11, 19 However, it was also reported that phosphorylation of Nur77 by JNK1 markedly enhances its degradation, 21 in line with an earlier observation that Nur77 is a short-lived protein. 22 Therefore, the phosphorylation by JNK seems to give rise to two apparently opposite destinies of Nur77, suggesting that other determinant(s) must be at work for the fate switching between degradation and mitochondria translocation. The underlying molecular mechanism, however, is unknown.
Smurf1 (Smad ubiquitination regulatory factor 1) and Smurf2, which are two close family members of C2-WW-HECT E3 ubiquitin ligases, were first identified as negative regulators of transforming growth factor-b/bone morphogenic protein signaling by downregulating R-Smads and transforming growth factor-b receptors. 23 In addition, Smurfs regulate many other important biological processes such as cell migration, cell polarity, transforming growth factor-b-induced epithelial-to-mesenchymal transition and bone homeostasis by targeting diverse substrates, including RhoA, Rap1B, Par6, MEKK2 and RUNX. [24] [25] [26] [27] [28] [29] [30] [31] A recent study showed that PKA could phosphorylate Smurf1 at its Thr306, thereby regulates axon formation by switching its substrate preference between Par6 and RhoA. 24 In this study, we found that Smurf1 could effectively block Nur77 degradation via regulating a non-K48-linked ubiquitination of Nur77, and the phosphorylation of Smurf1 at Thr306 by PKA is necessary for the activity of Smurf1 toward stabilizing Nur77. Thus, we have revealed a molecular mechanism for controlling the effect of JNK on Nur77, in that PKA/Smurf1 signaling antagonizes the JNK-promoted degradation of Nur77, favoring its stabilization to induce apoptosis triggered by the anticancer drug cisplatin.
RESULTS

Smurf1 stabilizes Nur77 by mediating non-K48-linked ubiquitination of Nur77
Nur77 is a short-lived protein and is involved in controlling a wide range of biological functions. 19, 22 In a search for E3 ligases that could regulate Nur77 stability, we surprisingly found that overexpression of wild-type Smurf1 (WT), but not catalytically inactive Smurf1-C699A mutant (CA), markedly increased the steady-state levels of Nur77 (Figure 1a) . In contrast, overexpression of Smurf2, a closely related family member of Smurf1, did not have such an effect (Figure 1b) , indicating a specific role of Smurf1 in regulating protein levels of Nur77. Consistently, overexpression of Smurf1 led to the accumulation of endogenous Nur77 in human cervical cancer HeLa cells (Figure 1c) , and knockdown of Smurf1 caused a significant reduction of endogenous Nur77 (Figure 1d ).
Of note, neither overexpressing nor knocking down of Smurf1 had significant effect on Nur77 mRNA levels (Supplementary Figure  S1A) , indicating that Smurf1-dependent regulation of Nur77 is not through enhancing transcription of Nur77.
To investigate the mechanism by which Smurf1 regulates Nur77 stability, we examined whether Smurf1 could protect Nur77 from degradation. For this purpose, we first examined the interaction between Smurf1 and Nur77. Indeed, both wild-type Smurf1 and Smurf1-C699A could coimmunoprecipitate with Nur77. It is Figure 1 . Smurf1 protects Nur77 from degradation by mediating atypical ubiquitination of Nur77. (a) Smurf1 overexpression increases the steady-state levels of Nur77. HEK293T cells were transiently transfected with indicated combinations of HA-tagged Nur77 and Myc-tagged wild-type Smurf1 (WT) or catalytically inactive Smurf1 mutant C699A (CA). Steady-state protein levels were determined by immunoblotting (IB). The b-actin levels were used as a loading control. (b) Smurf2 overexpression has no effect on protein levels of Nur77. Experimental conditions were same as in (a) except that Smurf2 was used. (c) Overexpression of Smurf1 increases the levels of endogenous Nur77. Endogenous Nur77 protein levels in HeLa cells transduced with control lentivirus or lentivirus encoding Flag-tagged Smurf1 (WT or CA) were detected by immunoblotting with anti-Nur77 antibody. (d) Knockdown of Smurf1 decreases endogenous Nur77 protein levels. HeLa cells were transduced with lentivirus encoding Smurf1 shRNAs or control shRNA, and the endogenous protein levels of Nur77 and Smurf1 were determined by immunoblotting. (e) Smurf1 associates with Nur77. HEK293T cells transfected with Flag-tagged Smurf1 (WT or CA) and HA-tagged Nur77 were subjected to anti-Flag immunoprecipitation (IP) followed by immunoblotting with anti-HA antibody to detect associated Nur77. (f ) In vitro interaction between Smurf1 and Nur77. His-tagged Nur77 and glutathione S-transferase (GST)/Smurf1 (WT or CA) produced and purified from bacteria were applied to GST-pull down assay. Associated Nur77 was detected with anti-Nur77 antibody. GST and GST/Smurf1 were determined by Ponceau S staining. (g) Smurf1 changes the ubiquitin-conjugation pattern of Nur77. Forty hours after transfection with indicated combinations of triple Flag-tagged Nur77, Myc-tagged Smurf1 (WT or CA) and HA-tagged ubiquitin (Ub), HEK293T cells were treated with MG-132 (20 mM) for another 4 h and then subjected to ubiquitination assay. Ubiquitin-conjugated Nur77 ((Ub) n -Nur77) were detected by immunoblotting with anti-HA antibody. (h) Smurf1 mediates atypical ubiquitination of Nur77. HEK293T cells transfected with combinations of triple Flag-tagged Nur77, Myc-tagged Smurf1 (WT) and different mutants of HA-tagged ubiquitin as indicated were subjected to ubiquitination assay 40 h after transfection. The K48 mutant is ubiquitin with all Lys residues except K48 mutated to Arg and R48 denotes ubiquitin with Lys48 alone mutated to Arg.
noteworthy that HA-tagged Nur77 appeared as doublets, and accumulation of Nur77 mainly occurred on the upper band when coexpressed with wild-type Smurf1, and correspondingly, most of the Smurf1-associated Nur77 was the upper band ( Figure 1e ). Moreover, we confirmed that Smurf1-C699A could trap endogenous Nur77 (Supplementary Figure S1B) , and Smurf1 was able to bind Nur77 directly in glutathione S-transferase pull-down assays using bacterial produced proteins ( Figure 1f) .
As a short-lived protein, Nur77 is ubiquitinated. Interestingly, overexpression of Smurf1 decreased the levels of high-molecularweight ubiquitin-conjugated Nur77 and promotes the formation of lower molecular weight ubiquitin conjugates (Figure 1g ). It is well established that K48-linked ubiquitin chains are targeted for proteasomal degradation and K63-linked chains exert nonproteolytic functions, 32 whereas the roles of other types of linkage through K6, K11, K27, K29 or K33 of ubiquitin remains unclear. 33 We hypothesized that Smurf1 may mediate unconventional ubiquitination of Nur77 to inhibit the K48-linked ubiquitin chain formation, therefore blocks its degradation. To test this, we used ubiquitin mutants K48 (all Lys residues except Lys48 mutated to Arg) and R48 (only Lys48 mutated to Arg) to examine the Smurf1-mediated ubiquitin-conjugation of Nur77. Remarkably, R48 but not K48 was able to be conjugated to Nur77 by Smurf1 (Figure 1h ), indicating that Smurf1-catalyzed ubiquitin chain formation on Nur77 is not through K48 linkage. We further generated a series of ubiquitin mutants that contain only K6, K11, K27, K29, K33 or K63 to examine which Lys residue(s) can be used to form ubiquitin-conjugated Nur77 by Smurf1. As shown in Supplementary Figure S1C , both ubiquitin mutants K6 and K27 could be conjugated to Nur77, suggesting a complicated assembly of ubiquitin chain by Smurf1. Thus, our results revealed that Smurf1 protects Nur77 from degradation by mediating atypical ubiquitination of Nur77.
Smurf1 antagonizes JNK-promoted Nur77 degradation Given that the Smurf1-enhanced accumulation of Nur77 is mainly the upper band and Nur77 is a phospho-protein, we tested whether the upper band was phosphorylated Nur77 that might be preferentially enriched when coexpressed with Smurf1. To this end, we immunoprecipitated HA-tagged Nur77 and treated it with calf intestinal alkaline phosphatase. Calf intestinal alkaline phosphatase treatment effectively diminished the upper band of Nur77, indicating that the upper band, which is protected by coexpression of Smurf1, is mainly phosphorylated Nur77 (Figure 2a ). To explore which kinase(s) might be responsible for the phosphorylation, we tested effects of different inhibitors for the kinases that had been reported to phosphorylate Nur77, including JNK, AKT, extracellular signal-regulated kinase, ribosomal S6 kinase, PKA and glycogen synthase kinase-3b, on Smurf1-mediated increase of phospho-Nur77. As shown in Figure 2b , JNK inhibitor SP600125 and PKA inhibitor H89 significantly inhibited Smurf1-induced accumulation of phosphoNur77 (lane 4 and lane 7), whereas extracellular signal-regulated kinase/ribosomal S6 kinase inhibitor U0126, PI3K/AKT inhibitor LY294002 or glycogen synthase kinase-3b inhibitor LiCl had no effect. These results suggested that both JNK and PKA are required for Smurf1-mediated increase of phospho-Nur77. To confirm this, we used dominant-negative mutants of PKA, JNK1 (JNK1-AF) and JNK2 (JNK2-AF) to examine the necessity of kinase activities of PKA and JNK. Indeed, coexpression of dominant-negative mutants of PKA or JNK1-AF, but not JNK2-AF significantly abolished the Smurf1-induced increase in Nur77 upper band (Figures 2c and d ), in agreement with a previous report that JNK1 but not JNK2 is responsible for Nur77 phosphorylation. 21 The previous study also showed that JNK1-mediated phosphorylation of Nur77 promoted Nur77 degradation through ubiquitin-proteasome pathway. 21 To address whether Smurf1 could inhibit JNK-promoted proteasomal degradation of Nur77, we compared the effects of Smurf1 and proteasome inhibitor MG-132 on steady-state levels of Nur77 in the presence or absence of JNK activator Anisomycin. As shown in Figure Smurf1-mediated stabilization of Nur77 is required for cisplatininduced apoptosis It has been shown that Nur77 is a potent death factor and is important for anticancer drugs, such as cisplatin to induce apoptosis in various cancer cells. In this process, JNK-dependent phosphorylation of Nur77 is essential for Nur77 to translocate from nucleus to mitochondria to trigger apoptosis. 11, 19 Remarkably, cisplatin treatment increased Nur77 levels through upregulating transcription of Nur77 Figure S4A) , and inhibiting JNK1 activity using JNK1-AF significantly decreased cisplatininduced apoptosis (Supplementary Figure S4B) . Consistently, inhibition of JNK activity strongly blocked cisplatin-induced Nur77 nuclear export, whereas treatment of JNK activator Anisomycin alone promoted nuclear export of Nur77 (Supplementary Figure S4C) , indicating that JNK1 activity is critical for cisplatin apoptotic effect, and cisplatin may induce Nur77 nuclear export by activating JNK1.
To investigate whether Smurf1-mediated protection of Nur77 is necessary for cisplatin-induced apoptosis in HeLa cells, we first verified the importance of Nur77 in cisplatin-triggered apoptosis using short hairpin RNA (shRNA) to specifically knockdown Nur77. Indeed, knocking down Nur77 prevented nuclear accumulation and subsequent nuclear export of Nur77 (Figure 3 Figure S6D) . Notably, overexpression of Smurf1 or Nur77 alone did not cause significant apoptosis, however, they markedly enhanced cisplatin-induced apoptosis (Supplementary Figure S7) . Taken together, our results showed that Smurf1-mediated stabilization of Nur77 is critical for cisplatininduced apoptosis.
Phosphorylation of Smurf1 by PKA is essential for Smurf1-mediated stabilization of Nur77 and cisplatin-induced apoptosis Although inhibiting JNK and PKA had similar inhibitory effects on Smurf1-induced accumulation of phospho-Nur77 (Figure 2b ), activation of JNK by Anisomycin caused Nur77 band upshifted and enhanced Nur77 degradation, whereas treatment of cyclic AMP (cAMP) analog 8-Br-cAMP, a potent activator of PKA, dramatically increased the steady-state levels of Nur77 (Figure 5a ), suggesting that PKA and JNK have different roles in regulating Nur77. To explore the mechanism of how PKA regulates Nur77, we first examined the effect of 8-Br-cAMP on protein levels of Nur77. As shown in Figure 5b , 8-Br-cAMP caused an increase of HA-tagged Nur77 in a dose-dependent manner, suggesting that PKA protects Nur77 from degradation. As both Smurf1 and PKA were able to protect Nur77, we investigated whether cAMP signaling and Smurf1 are in the same pathway to control the stability of Nur77. Knockdown of Smurf1 significantly diminished the upregulation of Nur77 induced by 8-Br-cAMP, suggesting that the cAMP signaling-mediated stabilization of Nur77 was dependent on Smurf1 (Figure 5c ). Consistent with the results obtained with exogenously expressed HA-tagged Nur77 in HEK293T cells, treatment of 8-Br-cAMP markedly increased endogenous protein levels of Nur77 (Figure 5d ) without significantly changing the mRNA levels of Nur77 (Supplementary Figure S8) , and knockdown of Smurf1 abolished the effect of 8-Br-cAMP on upregulating Nur77 (Figure 5d ). These results indicated that the cAMP signalingmediated stabilization of Nur77 is dependent on Smurf1.
A recent study showed that PKA could phosphorylate Smurf1 at Thr306 to switch its substrate preference between Par6 and RhoA, 24 we thus investigated whether the PKA-dependent Smurf1 phosphorylation is relevant for Smurf1-mediated stabilization of Nur77. In the absence of PKA inhibitor H89, overexpression of either wild-type Smurf1 or Smurf1-T306D, a phospho-mimicking mutant of Smurf1 at Thr306, elevated the levels of Nur77. Remarkably, in the presence of H89, only Smurf1-T306D but not wild-type Smurf1 upregulated the levels of Nur77, indicating that PKA-mediated phosphorylation of Smurf1 at Thr306 is necessary for blocking Nur77 degradation ( Figure 5e ).
As Smurf1-mediated stabilization of Nur77 is required for cisplatin-induced apoptosis, and the phosphorylation of Smurf1 at Thr306 by PKA is essential for its activity to stabilize Nur77, we next examined whether PKA activity is required for Figure 3 . Smurf1 is necessary for accumulation of Nur77 in the nucleus and subsequent translocation to mitochondria during cisplatin treatment. HeLa cells transduced with lentivirus encoding control shRNA, Smurf1 shRNA or Nur77 shRNA were treated with or without 10 mM cisplatin for 36 h as indicated, and endogenous Nur77 (red) and mitochondria marker protein Hsp60 (green) were detected by immunofluorescence assay. The nuclei were stained with 4' ,6-diamidino-2-phenylindole, DAPI (blue) and colocalization of Nur77 and Hsp60 are marked with yellow arrowheads.
Nur77-mediated apoptosis. Indeed, pretreatment of PKA inhibitor H89 or overexpressing dominant-negative mutant of PKA markedly diminished the increase of Nur77 caused by cisplatin (Supplementary Figure S9A and Supplementary Figure S9B) , and correspondingly, significantly inhibited the apoptosis caused by cisplatin (Figure 6a, Supplementary Figures S9C and S10A) . Furthermore, only coexpression of Smurf1-T306D but not wildtype Smurf1 or Smurf1-C699A could restore cisplatin-induced apoptosis in H89-treated HeLa cells (Figure 6b and Supplementary Figure S10B ), indicating that PKA-mediated phosphorylation of Smurf1 at Thr306 is required for cisplatin to induce apoptosis.
On the other hand, although 8-Br-cAMP by itself caused little apoptosis, it dramatically enhanced cisplatin-caused apoptosis, indicating a synergistic effect of cAMP signaling and cisplatin on apoptosis induction (Figure 6c, Supplementary Figure S10C and Figure 6d ). Correspondingly, co-treatment of 8-Br-cAMP and cisplatin resulted in a much more drastic increase of Nur77 (Figure 6e ), and this augment of Nur77 was also dependent on Smurf1 (Figure 6f) . Moreover, the apoptosis induced by cotreatment of cisplatin and 8-Br-cAMP was significantly inhibited by knocking down either Nur77 or Smurf1 (Figure 6g , Supplementary Figure S10D and Figure 6h ). These results indicated that PKA has a key role in cisplatin-induced apoptosis through regulating Smurf1 activity toward protecting Nur77 from degradation.
Furthermore, the necessity of PKA activity for cisplatin-induced apoptosis and the synergistic effect of cAMP/PKA signaling and cisplatin on apoptosis rates were confirmed in different types of cancer cells, including stomach cancer cell line BGC-823, colorectal cancer cell line HCT116, hepatocellular cancer cell line HepG2 and osteosarcoma cancer cell line U2OS (Supplementary Figure S11) .
DISCUSSION
It was known that the JNK-mediated phosphorylation of Nur77 is essential for the induction of apoptosis, 19 however, it promotes the degradation of Nur77 in the meantime, which would preclude its cellular function. 21 Our study here revealed an integrating effect of the signaling pathways of PKA/Smurf1 and JNK/Nur77 that is important for controlling the steady-state levels of Nur77 and the Nur77-dependent apoptosis caused by cisplatin (Figure 7) . In untreated cells, Nur77 is phosphorylated by JNK and is degraded through ubiquitin-proteasome pathway. Cisplatin treatment has dual roles in regulating Nur77, enhancing Nur77 transcription and promoting Nur77 nuclear export by activating JNK. The PKA/Smurf1 pathway is critical for preventing degradation of Nur77, thereby working together with JNK signaling to tune up apoptotic potency of cisplatin.
The second messenger cAMP transfers numerous extracellular signaling into cells to regulate a large variety of cellular functions including apoptosis. 34 Both enhancement and blockage of apoptosis had been reported for cAMP signaling pathway. As for the pro-apoptotic effect of cAMP, it has long been known that PKA activity is required for cAMP-promoted apoptosis, however, the exact signaling pathway and downstream protein targets of PKA necessary for cAMP-promoted apoptosis were not clear. 35, 36 In this study, we discovered that through mediating the phosphorylation of Thr306 in Smurf1, cAMP/PKA signaling enables Smurf1 to block JNK-promoted Nur77 degradation. Therefore, in addition to the previous report that phosphorylation of Thr306 switches substrate preference of Smurf1 between Par6 and RhoA, a novel role of PKAmediated Thr306 phosphorylation is for Smurf1 to stabilize Nur77 by mediating its atypical ubiquitination. Smurf1 and Smurf2 are two close-related family members of C2-WW-HECT E3 ubiquitin ligases and they share redundant functions in regulating transforming growth factor-b/bone morphogenic protein signaling pathway and cell polarity. 23, 26 Moreover, a recent study showed that both Smurfs may stabilize MDM2, an E3 ubiquitin ligase for p53, thereby enhance p53 degradation and inhibit apoptosis in untreated cells. 37 Despite the high homology and functional redundancy between Smurf1 and Smurf2, we found that Smurf1 but not Smurf2 is necessary for Nur77-dependent apoptosis through blocking Nur77 degradation in response to cAMP/PKA signaling, indicating a distinct role of Smurf1 in mediating Nur77 signaling pathways.
Functions of K48-and K63-linked ubiquitin chains are best characterized so far and it is believed that the K48-linked ubiquitin chains are responsible for proteasomal degradation, whereas K63-linked ubiquitin chains are involved in other processes, such as DNA repair, endocytosis and regulation of kinase activity. 32 However, the roles of ubiquitin linkage through K6, K11, K27, K29 or K33 are not well understood. 33 A recent study showed that RING type E3 ligase SCF b-TrCP stabilizes oncoprotein Myc by regulating an alternative ubiquitination event that requires K33, K48 and K63 of ubiquitin, which antagonizes SCF Fbw7 -mediated K48-linked polyubiquitin chain formation. 38 Here, we showed that Smurf1 mediates an unconventional ubiquitination of Nur77 that may involve K6 and K27 linkage, thereby prevents K48-dependent ubiquitination-induced Nur77 degradation, presenting the first example of atypical ubiquitination regulated by Smurf1. Thus, our study demonstrated that in addition to targeting various substrates for degradation through regulating the canonical K48-linked ubiquitination, Smurf1 may exert novel regulatory functions on its substrates by mediating assembly of atypical ubiquitin chains.
Cisplatin is one of the most widely used anticancer drugs in chemotherapy of many types of solid tumors, including testicular, Figure 6 . cAMP/PKA signaling has a key role in cisplatin-induced apoptosis via regulating Smurf1-dependent stabilization of Nur77. (a) PKA activity is required for cisplatin-induced apoptosis. HeLa cells were pretreated with or without 2 mM H89 for 9 h, followed by a treatment with 10 mM cisplatin for another 48 h before subjected to flow cytometry assay. Significant difference (Po0.001) is indicated (***). (b) Phosphorylation of Smurf1 at Thr306 is critical for cisplatin-induced apoptosis. HeLa cells transduced with control lentivirus or lentivirus encoding Flag-tagged Smurf1 (WT, T306D or CA) were pretreated with or without 2 mM H89 for 9 h, and then treated with 6 mM cisplatin for another 48 h as indicated. The apoptotic rates were determined using flow cytometry. Significant difference (Po0.001) is indicated (***). (c, d) Synergistic effect of 8-Br-cAMP and cisplatin on apoptosis induction. HeLa cells were treated with indicated combinations of 5 mM cisplatin and 100 mM 8-Br-cAMP, and the rates of apoptosis were determined using flow cytometry 48 h after treatment (c) and cleavage of PARP was detected by immunoblotting 36 h post-treatment (d). Significant difference (Po0.001) is indicated (***). Effect of 8-Br-cAMP on the activation of PKA was confirmed by immunoblotting phosphorylation levels of its substrate CREB (p-CREB). (e) Cisplatin and 8-Br-cAMP synergistically increase the steady-state levels of Nur77. HeLa cells were treated with indicated combinations of 6 mM cisplatin and 100 mM 8-Br-cAMP for 8 h, and then subjected to immunoblotting to determine the protein levels of Nur77. (f ) Enhancement of protein levels of Nur77 is dependent on Smurf1. HeLa cells transduced with control lentivirus or lentivirus encoding control shRNA or Smurf1 shRNA were co-treated with cisplatin (6 mM) and 8-Br-cAMP (100 mM) for 8 h, and the protein levels of Nur77 and Smurf1 were determined by immunoblotting. (g, h) Synergistic effect of cisplatin and 8-Br-cAMP on apoptosis induction is dependent on both Nur77 and Smurf1. HeLa cells transduced with control lentivirus or lentivirus encoding control shRNA or shRNA against Smurf1 or Nur77 were co-treated with cisplatin (5 mM) and 8-Br-cAMP (100 mM). The apoptotic rates were examined by flow cytometry 48 h after treatment of cisplatin and 8-Br-cAMP (g) and PARP cleavage detected by immunoblotting 36 h post-treatment (h). Significant difference (Po0.001) is indicated (***).
bladder, head and neck, lung, ovarian, cervical and colorectal cancer. 39 Unfortunately, resistance to cisplatin, either intrinsic or acquired during cisplatin treatment, is a major limitation for its efficacy. 40 Although many different mechanisms for cisplatininduced apoptosis as well as the development of cisplatin resistance have been proposed, the underlying molecular details remains obscure. 41, 42 Our study provides an alternative view on the molecular mechanism for cisplatin resistance, and more practicably, it points out a potential clinical combination use of cAMP analogs and cisplatin to significantly enhance the efficacy of cisplatin.
MATERIALS AND METHODS
Chemicals and antibodies
The chemical reagents Anisomycin, 8-Br-cAMP, SP600125, cycloheximide, LiCl, Cisplatin and Leptomycin B were from Sigma-Aldrich (St Louis, MO, USA); LY294002, U0126 were from Cell Signaling (Boston, MA, USA); H89 was from Beyotime (Shanghai, China); MG-132 was from Boston Biochem (Cambridge, MA, USA). The anti-Flag M2 and anti-Hsp60 monoclonal antibodies were from Sigma-Aldrich; anti-c-Myc, anti-b-actin, anti-a-tubulin and anti-Lamin B antibodies were from Santa Cruz (Dallas, TX, USA); rat anti-HA monoclonal antibody was from Roche (Mannheim, Germany); anti-Smurf1 antibody was from Abcam (Cambridge, MA, USA); anti-Nur77, anti-JNK, anti-p-JNK, anti-p-c-Jun, anti-p-AKT, anti-p-ribosomal S6 kinase, anti-p-CREB (cAMP response element-binding protein), anti-p-GSK3b and anti-poly ADP-ribose polymerase antibodies were from Cell Signaling.
DNA constructs
Human Smurf1 (wild type and C699A) and Smurf2 (wild type and C716A) have been previously described. 29, 43 Phospho-mimicking mutant Smurf1-T306D was generated by PCR-based site-directed mutagenesis. 24 Triple HA-and Flag-tagged Nur77 expression plasmids were constructed by subcloning PCR product of human Nur77 complementary DNA into pCMV5 vector and confirmed by sequencing. Flag-tagged dominant-negative mutants JNK1-AF and JNK2-AF expression plasmids were generated using site-directed mutagenesis with substitution of Thr183 to Ala in human JNK1 and Tyr185 to Phe in human JNK2, respectively, according to previous reports. 44, 45 Flag-tagged dominant-negative mutant of human cAMP-dependent protein kinase regulatory subunit R1a (dominantnegative mutants of PKA) was generated by site-directed mutagenesis with substitutions of Gly201 to Glu, Gly325 to Asp and Arg333 to His according to previous report. 46 HA-tagged off ubiquitin mutants with Lys to Arg mutation at appropriate sites were obtained by site-directed mutagenesis.
For gene silencing, the sequences of Smurf1 shRNA-1 and -2 are 5 0 -GGTT ACACCACATCATGAA-3 0 and 5 0 -TGAAGGAACGGTGTATGAA-3 0 ; and those for Nur77 shRNA-1 and -2 are 5 0 -GGAGAAGATCCCTGGCTTT-3 0 and 5 0 -GGAC AGAGCAGCTGCCCAA-3 0 ; and scramble sequence 5 0 -TTCTCCGAACGTGGC ACGA-3 0 was used as a control shRNA. The shRNAs were generated by using pLL3.7 vector (Addgene, Cambridge, MA, USA).
Cell culture, transfection and lentivirus infection
Human embryonic kidney HEK293T cells, human cervical cancer HeLa cells, human osteosarcoma U2OS cells and human hepatoma HepG2 cells were grown in high-glucose Dulbecco's modified Eagle's medium (Invitrogen, Grand Island, NY, USA), and human gastric cancer BGC-823 cells and human colorectal carcinoma HCT116 cells were grown in Roswell Park Memorial Institute-1640 medium (Invitrogen), all supplemented with 10% (v/v) fetal bovine serum (Invitrogen) and 100 units/ml streptomycin and penicillin (Millipore, Billerica, MA, USA), at 37 1C in a humidified 5% CO 2 incubator. HEK293T cells were transiently transfected using the calcium phosphate method as previously described. 47 Recombinant lentivirus was generated by the ViraPower Lentiviral Expression System (Invitrogen) and was used to infect HeLa cells for shRNA or protein expression.
Quantitative RT-PCR Total RNA was extracted from cells using Trizol (Invitrogen), and complementary DNA was synthesized using PrimeScript High Fidelity Reverse Transcriptase kit (TaKaRa, Dalian, China). Real-time amplification of transcripts was performed using a Mastercycler EP gradient S RealPlex 2 (Eppendorf, Hamburg, Germany). The expression of target transcripts was normalized to the internal control gene GAPDH, and relative changes of gene expression were determined using the 2 À DDCt method. The primers for Nur77 are 5 0 -ACACCTTCCTCTACCAGCTG-3 0 (forward) and 5 0 -CCGTAC ACCTGGAAGTCCTC-3 0 (reverse); and for GAPDH are 5 0 -CATGAGAAGTATGA CAACAGCCT-3 0 (forward) and 5 0 -AGTCCTTCCACGATACCAAAGT-3 0 (reverse).
Immunoprecipitation, immunoblotting, glutathione S-transferase pull-down and ubiquitination assays
Immunoprecipitation, immunoblotting, glutathione S-transferase pulldown, ubiquitination assays were all carried out as described previously. 47 Briefly, cells were lysed using ice-cold lysis buffer TNTE 0.5% (0.5% Triton X-100, 50 mM Tris-HCl, pH 7.5, 150 mM NaCl and 1 mM EDTA) containing 10 mg/ml pepstatin A, 10 mg/ml leupeptin and 1 mM phenylmethylsulfonyl fluoride (PMSF). The total cell lysates were then applied to immunoblotting assays or immunoprecipitation assays using appropriate antibodies. For Smurf1 and Nur77 interaction assay, lysis buffer TNPE 0.2% (0.2% NP-40, 20 mM Tris-HCl, pH 7.5, 150 mM NaCl and 1 mM EDTA) was used instead of TNTE 0.5%. For ubiquitination assay, the cell lysates were subjected to anti-Flag immunoprecipitation, eluted by boiling in 1% SDS for 5 min, and diluted 10 times in lysis buffer and re-immunoprecipitated with anti-Flag (2 Â IP). The ubiquitin-conjugated proteins were detected by immunoblotting.
Immunofluorescence assay HeLa cells grown on glass coverslips were washed in phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde and permeabilized with 0.25% Triton X-100. Endogenous Nur77 was detected using rabbit antiNur77 antibody (Cell Signaling) followed by Alexa Fluor 555-conjugated donkey antibody to rabbit immunoglobulin (Invitrogen). HA-tagged Nur77 was detected using rat anti-HA antibody (Roche) followed by Alexa Fluor 488-conjugated donkey antibody to rat immunoglobulin G (Invitrogen). Hsp60 was stained using mouse anti-Hsp60 antibody (Sigma-Aldrich) followed by Alexa Fluor 488 or 555-conjugated donkey antibody to mouse immunoglobulin G. Images were obtained using a ZEISS LSM 780 confocal microscope and ZEN 2010 software (Carl Zeiss GmbH, Jena, Germany).
Apoptosis analysis
Cells cultured in six-well plates were treated with indicated chemicals, trypsinized and collected. The cells were washed in PBS, fixed with 70% ethanol overnight, washed and incubated in PBS with 100 units/ml RNase A at 37 1C for 30 min, and stained with 50 mg/ml propidium iodide in PBS for 30 min at 37 1C in the dark. The percentages of apoptotic cells were measured by determining cell proportion in sub-G1 phase using a Beckman Coulter Epics XL flow cytometer (Beckman Coulter, Indianapolis, IN, USA). 
